( ed from time to time in the Company'sS...)Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril,Health

ed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2003, and Quarterly Reports on Form 10-Q for the periods ending June 30, 2003, September 30, 2003, and December 31, 2003. Actual results may differ materially from those projected.

Please see package insert for full prescribing information

Trademarks not owned by Daiichi Sankyo, Inc., are the property of their respective owners.

    *  Blood pressure reduction reported as least square means, last

       observation carried forward (LOCF)


    ** Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral

       is a registered trademark of Merck Sante s.a.s, subsidiary of Merck

       KGaA, Darmstadt, Germany.


    1. Stage 2 hypertension = systolic blood pressure greater than or equal to

       160 mm Hg or a diastolic blood pressure greater than or equal to 100 mm

       Hg, as defined by The Seventh Report of the Joint National Committee on

       Prevention, Detection, Evaluation and Treatment of High Blood Pressure

       (JNC 7)

    2. JNC 7 = The Seventh Report of the Joint National Committee on

       Prevention, Detection, Evaluation and Treatment of High Blood Pressure

       (JNC 7), which issued new guidelines in 2003 for hypertension

       prevention and management.

    3. http://www.americanheart.org/presenter.jhtml?identifier=4621 Site

       accessed 5/11/2007

    4. http://www.americanheart.org/presenter.jhtml?identifier=2114 Site

       accessed 5/17/2007

    5. http://www.americanheart.org/presenter.jhtml?identifier=4621 Site

       accessed 5/11/2007

CONTACT: Bill Heineke, +1-
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
4. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
5. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
6. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
7. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
8. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
9. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
10. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
11. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes